Tafolecimab cuts LDL-C over 65% as monotherapy in Phase 3 trial, offering a statin-free option for hypercholesterolemia ...

Pasritamig plus JNJ-9401 produced PSA reductions of at least 50% in 73% of heavily pretreated metastatic prostate cancer ...

UMBRAA masking strategy targets psychedelic trial unblinding bias. With FDA's July 2026 guidance now live, here's what it ...

Icotrokinra meets ACR20 endpoint in Phase 3 psoriatic arthritis trial, with 58% of biologic-naive patients achieving response ...

QIAGEN selects Medrio EDC to streamline in vitro diagnostic studies with cost control and internal form configuration ...

FDA's reviews of Zolgensma, Luxturna, and Hemgenix reveal critical gaps in AAV trial design, CMC standards, and long-term ...

BRII-179 showed 32% HBsAg loss durability at 24 weeks post-treatment in the Phase 2b ENRICH study, with consistent results ...

ATG-201 Phase I trial opens in China for B cell autoimmune diseases, testing a CD19×CD3 bispecific with masking technology to ...

Eton's ET-700 shows better tolerability than GALZIN but reduced efficacy in Wilson disease pilot study with 12 patients per ...

Citius Oncology presents LYMPHIR quality-of-life data from pivotal Study 302 at EORTC meeting, supporting formulary ...

ICON's AI-directed video engine cuts clinical trial video production time by 90%, streamlining site selection and training ...

Clinical research sites report trial complexity as their top operational problem, with 41% naming it their biggest challenge ...